FABTECH vs NEPHROPLUS: Stock Comparison
Nephrocare Health Services Ltd is the larger company by market capitalisation. Fabtech Technologies Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Nephrocare Health Services Ltd shows lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
FABTECH leads 9; NEPHROPLUS leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Medical Equipment & Supplies | — |
Price
| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| Live Price | ₹147.62 | ₹697.35 |
| Day Change | 0.39% | 1.47% |
| Volume | 1.64 L | 1.46 L |
| 52-Week High | ₹262.8 | ₹769.75 |
| 52-Week Low | ₹132.7 | ₹446 |
| Distance from 52W High | -43.83% | -9.41% |
Valuation
| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹659 Cr | ₹6,991 Cr |
| P/E Ratio | 13.38x | 89.97x |
| P/B Ratio | 1.55x | 6.19x |
| EPS | ₹10.95 | ₹7.66 |
| Book Value | ₹109.44 | ₹111 |
| Dividend Yield | 0.41% | 0% |
Growth
| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 17.5% | 0% |
| EPS Growth (TTM YoY) | 23.4% | 0% |
| Qtr Sales Growth | 17.5% | 21.2% |
| Qtr Profit Growth | 46.2% | 22.1% |
Profitability & Leverage
| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| ROE | 12.5% | 9.06% |
| ROCE | 13.6% | 15.5% |
| Net Margin | 11.28% | 7.69% |
| Operating Margin | 8.52% | 22.4% |
| Debt to Equity | 0.17x | 0.07x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | FABTECH | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 68.94% | 21.07% |
| FII Holding | 0.02%▼ 0.06 pp | 8.78%▼ 1.16 pp |
| DII Holding | 2.45%▲ 0.3 pp | 9.05%▲ 0.4 pp |
| Public Holding | 28.58%▼ 0.25 pp | 18.32%▲ 0.76 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Fabtech Technologies Limited and Nephrocare Health Services Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.